1JS Stock Overview
A commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Shield Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.034 |
| 52 Week High | UK£0.09 |
| 52 Week Low | UK£0.0095 |
| Beta | 1.52 |
| 11 Month Change | -37.04% |
| 3 Month Change | -15.00% |
| 1 Year Change | -46.03% |
| 33 Year Change | -90.86% |
| 5 Year Change | -98.45% |
| Change since IPO | -98.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1JS | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 11.5% | -1.2% | -0.02% |
| 1Y | -46.0% | -20.1% | 8.2% |
Return vs Industry: 1JS underperformed the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: 1JS underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 1JS volatility | |
|---|---|
| 1JS Average Weekly Movement | 16.1% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1JS's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1JS's weekly volatility has decreased from 31% to 16% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 73 | Anders Lundstrom | www.shieldtherapeutics.com |
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Shield Therapeutics plc Fundamentals Summary
| 1JS fundamental statistics | |
|---|---|
| Market cap | €26.82m |
| Earnings (TTM) | -€34.73m |
| Revenue (TTM) | €20.62m |
1.3x
P/S Ratio-0.8x
P/E RatioIs 1JS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1JS income statement (TTM) | |
|---|---|
| Revenue | US$21.47m |
| Cost of Revenue | US$13.65m |
| Gross Profit | US$7.83m |
| Other Expenses | US$43.99m |
| Earnings | -US$36.17m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.046 |
| Gross Margin | 36.44% |
| Net Profit Margin | -168.42% |
| Debt/Equity Ratio | 3,637.5% |
How did 1JS perform over the long term?
See historical performance and comparison